|
業務類別
|
Biotechnology |
|
業務概覽
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
| 公司地址
| 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 781 312-3013 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.jadebiosciences.com |
| 員工數量
| 55 |
| Dr. Hetal Kocinsky, M.D. |
Chief Medical Officer |
-- |
01/05/2025 |
| Dr. Andrew James King, PhD |
Chief Scientific Officer and Head, Research and Development |
-- |
01/05/2025 |
| Mr. Tom Frohlich |
Chief Executive Officer and Director |
-- |
01/07/2025 |
| Mr. Bradford D. Dahms |
Chief Financial Officer and Treasurer |
-- |
01/07/2025 |
| Mr. Jonathan Quick |
Senior Vice President, Finance and Treasurer |
-- |
01/05/2025 |
| Ms. Elizabeth Balta, J.D. |
General Counsel and Corporate Secretary |
-- |
01/05/2025 |
|
|
| Mr. Tom Frohlich |
Chief Executive Officer and Director |
01/07/2025 |
| Mr. Tomas Kiselak |
Independent Director |
01/05/2025 |
| Dr. Chris Cain, PhD |
Independent Director |
01/05/2025 |
| Dr. Lawrence Otto Klein, PhD |
Independent Director |
01/05/2025 |
| Ms. Erin M. Lavelle |
Independent Director |
01/05/2025 |
| Mr. Eric L. Dobmeier, J.D. |
Independent Director |
01/05/2025 |
|
|
|
|
